Ignite Creation Date:
2025-12-24 @ 5:44 PM
Ignite Modification Date:
2025-12-29 @ 6:54 AM
Study NCT ID:
NCT01186068
Status:
COMPLETED
Last Update Posted:
2010-11-24
First Post:
2010-08-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dose Response Study of Patients With Erythematous Rosacea
Sponsor:
Vicept Therapeutics, Inc.
Organization:
Study Overview
Official Title:
A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of the Dose-Response Profile of V-101 Cream in Subjects With Erythematous Rosacea
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of V-101 Cream in patients with erythematous(redness) rosacea.
Detailed Description:
Patients must have moderate to severe erythematous (facial redness) rosacea
* Male and female patients must be at least 18 years old and in good general health
* Female patients must not be pregnant or nursing
* Male and female patients must be at least 18 years old and in good general health
* Female patients must not be pregnant or nursing
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: